Trial Profile
A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs FPT 155 (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Five Prime Therapeutics
- 06 Jan 2022 Status changed from recruiting to completed.
- 03 Nov 2020 According to a Five Prime Therapeutics media release, patients with warm/hot tumor types continue to be enrolled at the 560mg dose.
- 03 Nov 2020 According to a Five Prime Therapeutics media release, the first cohort has been cleared and the second cohort is open for enrollment in a dose escalation of FPT155 and pembrolizumab in patients with non-small cell lung cancer.